A drinkable formulation of alendronate: potential to increase compliance and decrease upper GI irritation

Area of Science:

• Pharmacology
• Public Health
• Geriatrics

Background:

• Osteoporosis is a significant public health concern, necessitating effective pharmacological interventions.
• Alendronate, the first anti-fracture agent, is widely prescribed but suffers from poor patient compliance (50-60% discontinuation within a year).
• Dysphagia and gastrointestinal concerns are primary barriers to long-term alendronate adherence, increasing fracture risk.

Purpose of the Study:

• To review strategies for improving patient adherence to alendronate therapy for osteoporosis.
• To highlight the benefits of novel, patient-friendly alendronate formulations.
• To focus on the recently developed Bonasol 70 mg oral solution as a potential adherence-improving agent.

Main Methods:

• Review of existing literature on osteoporosis pharmacotherapy and patient adherence.
• Analysis of challenges associated with traditional alendronate tablet administration.
• Evaluation of the characteristics and potential advantages of oral alendronate solutions.

Main Results:

• Poor adherence to oral alendronate tablets is a widespread issue, linked to swallowing difficulties and GI side effects.
• Drinkable alendronate formulations offer enhanced convenience, ease of administration, and potentially fewer GI adverse effects.
• Novel soluble alendronate products are cost-equivalent to generic alendronate tablets.

Conclusions:

• Improving patient adherence is critical for effective osteoporosis management and fracture prevention.
• Drinkable alendronate formulations represent a promising approach to enhance long-term treatment compliance.
• Bonasol 70 mg oral solution warrants consideration as a more acceptable alternative for osteoporotic patients.